{
    "clinical_study": {
        "@rank": "63619", 
        "acronym": "HALO", 
        "arm_group": [
            {
                "arm_group_label": "Cisplatin, Pemetrexed, Debio 0932", 
                "arm_group_type": "Experimental", 
                "description": "Cisplatin, Pemetrexed, Debio 0932"
            }, 
            {
                "arm_group_label": "Cisplatin, Gemcitabine, Debio 0932", 
                "arm_group_type": "Experimental", 
                "description": "Cisplatin, Gemcitabine, Debio 0932"
            }, 
            {
                "arm_group_label": "Docetaxel, Debio 0932", 
                "arm_group_type": "Experimental", 
                "description": "Docetaxel, Debio 0932"
            }
        ], 
        "brief_summary": {
            "textblock": "Part A of this study will investigate the Maximum Tolerated Dose of Debio 0932 in\n      combination with standard of care chemotherapy for the first- and second-line treatment of\n      advanced NSCLC."
        }, 
        "brief_title": "A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer", 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Part A of this study will determine the Maximum Tolerated Dose of Debio 0932 in combination\n      with cisplatin/pemetrexed and cisplatin/gemcitabine in treatment-na\u00efve patients with Stage\n      IIIb or IV NSCLC, and with docetaxel in previously treated patients with Stage IIIb or IV\n      NSCLC.\n\n      Escalating doses of Debio 0932 will be given to subsequent patients in combination with\n      standard doses of these 3 background chemotherapies."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of NSCLC with confirmed squamous or non-squamous tumour histology, without\n             known EGFR mutation\n\n          -  Advanced or metastatic disease (Stage IIIb or IV)\n\n          -  Patients to be treated with cisplatin/gemcitabine or cisplatin/pemetrexed: No\n             previous systemic treatment with chemotherapy, targeted therapy or investigational\n             agents (except adjuvant therapy if > 6 months ago); Patients to be treated with\n             docetaxel: \u2265 1 previous treatment with chemotherapy\n\n          -  Measurable disease by the RECIST criteria\n\n          -  ECOG performance score 0-1\n\n          -  Life expectancy \u2265 3 months\n\n          -  Adequate bone marrow-, renal- and hepatic function\n\n          -  LVEF \u2265 55% on cardiac ultrasound\n\n        Exclusion Criteria:\n\n          -  Symptomatic brain metastases\n\n          -  Gastro-intestinal disorders that could affect drug absorption (including, but not\n             limited to, major abdominal surgery, significant bowel obstruction, ulcerative\n             colitis, Crohn's disease)\n\n          -  Concurrent treatment with any other systemic anti-cancer therapy\n\n          -  Serious concomitant uncontrolled medical conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714037", 
            "org_study_id": "Debio 0932-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cisplatin, Pemetrexed, Debio 0932", 
                    "Cisplatin, Gemcitabine, Debio 0932", 
                    "Docetaxel, Debio 0932"
                ], 
                "description": "Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg QD.", 
                "intervention_name": "Debio 0932", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cisplatin, Pemetrexed, Debio 0932", 
                    "Cisplatin, Gemcitabine, Debio 0932"
                ], 
                "description": "Cisplatin 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cisplatin, Pemetrexed, Debio 0932", 
                "description": "Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cisplatin, Gemcitabine, Debio 0932", 
                "description": "Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Docetaxel, Debio 0932", 
                "description": "Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Docetaxel", 
                "Pemetrexed", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Safety, efficacy, HSP90, Debio 0932, standard of care treatment, NSCLC", 
        "lastchanged_date": "October 7, 2013", 
        "link": {
            "description": "Site Debiopharm SA", 
            "url": "http://www.debiopharm.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France"
                    }, 
                    "name": "Centre GF Leclerc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }, 
                    "name": "Centre L\u00e9on B\u00e9rard"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France"
                    }, 
                    "name": "Institut de Canc\u00e9rologie de l'Ouest- Institut Ren\u00e9 Gauduchau"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France"
                    }, 
                    "name": "Institut Claudius Regaud"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitari Vall d'Hebron"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Puerta de Hierro Majadahonda"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seville", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Virgen del Roc\u00edo"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newcastle", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Freeman Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I-II Evaluation of the Safety and Efficacy of the Oral HSP90 Inhibitor Debio 0932 in Combination With Standard of Care in first-and Second-line Therapy of Patients With Stage IIIb or IV Non-small Cell Lung Cancer-the HALO Study (HSP90 Inhibition And Lung Cancer Outcomes)", 
        "overall_contact": {
            "last_name": "Silvano Brienza, MD", 
            "phone": "+41 21 321 01 11"
        }, 
        "overall_official": [
            {
                "affiliation": "Centre GF Leclerc, Dijon, France", 
                "last_name": "Nicolas Isambert, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut Claudius Regaud, Toulouse, France", 
                "last_name": "Jean-Pierre Delord, PR", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre L\u00e9on B\u00e9rard, Lyon, France", 
                "last_name": "J\u00e8r\u00f4me Fayette, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut de Canc\u00e9rologie de l'Ouest- Institut Ren\u00e9 Gauduchau, Nantes, France", 
                "last_name": "Jaafar Bennouma, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario Virgen del Roc\u00edo, Seville, Spain", 
                "last_name": "Luis Paz-Ares, PR", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitari Vall d'Hebron, Barcelone, Spain", 
                "last_name": "Enriqueta Felip, PR", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Puerta de Hierro Majadahonda, Madrid, Spain", 
                "last_name": "Mariano Provencio, PR", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Freeman Hospital, Newcastle, UK", 
                "last_name": "Ruth Plummer, PR", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Occurrence of Dose Limiting Toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714037"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in vital signs and ECOG PS", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 of each treatment cycle until disease progression or study drug toxicity"
            }, 
            {
                "measure": "Incidence of AEs and SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "Every treatment cycle until disease progression or study drug toxicity"
            }, 
            {
                "measure": "Incidence of laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "2 to 4 times every treatment cycle until disease progression or study drug toxicity"
            }, 
            {
                "measure": "Incidence of treatment discontinuations due to AEs and SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "Every treatment cycle until diseases progression or study drug toxicity"
            }, 
            {
                "measure": "Change in LVEF", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and after 4 weeks of treatment"
            }, 
            {
                "measure": "Pharmacokinetic parameters of Debio 0932 and its metabolite Debio 0932-MET1", 
                "safety_issue": "Yes", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "Pharmacokinetic parameters of cisplatin/pemetrexed, cisplatin/gemcitabine, and docetaxel", 
                "safety_issue": "Yes", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "Best overall tumor response", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "Pharmacodynamic biomarkers", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "Pharmacogenomic, tumour pharmacogenetic, proteomic, and pharmacogenetic factors predictive of response to Debio 0932", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "source": "Debiopharm International SA", 
        "sponsors": {
            "collaborator": {
                "agency": "INC Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Debiopharm International SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}